ReviewJAAD international2025
Panniculitis in dermatomyositis: A systematic review of the clinicopathologic features.
Review in JAAD international, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- [Panniculitis : Patterns and clues].Pathologie (Heidelberg, Germany) · 2026Article
- Anti-nuclear Matrix Protein 2 Antibody-Positive Dermatomyositis Relapse With Preceding Panniculitis.Cureus · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Panniculitis in patients with dermatomyositis (PDMS) is rare. Objectives: Assess the clinicopathologic features described for PDMS. Methods: A systematic review of the PubMed/MEDLINE database was performed. We included cases with dermatomyositis (DMS) and confirmed panniculitis (histology/imaging). Extracted data included demographics, global region of origin, comorbidities, hallmark/nonhallmark features, muscle disease, panniculitis onset relative to classical DMS, symptomatology, physical findings, triggers, autoantibodies, extracutaneous involvement, histopathology, treatment, and prognosis. Results: Fifty-eight studies were included (91 patients). PDMS primarily occurred in relatively young women (mean age 35 years, female to male ratio 4.4:1). Adults predominated (adult:juvenile ratio 2.6:1). All had hallmark DMS features. A minority had nonhallmark findings. <1/4 reported extracutaneous involvement (pulmonary complications predominated). Cancer-associated disease was uncommon (7.4%). Panniculitis occurred before/simultaneously/after features of classical DMS. The clinical and histopathologic findings mimic lupus panniculitis, although lipoatrophy was uncommon (12.7%). A lobular/lobular predominant, lympoplasmacytic panniculitis was most common. Treatment regimens included combinations of systemic steroids/traditional steroid-sparers/Janus kinase inhibitors/biologics. The majority had a good/complete response (67.3%), but recalcitrant disease (22.4%) was reported. Limitations: Retrospective nature, inconsistent reporting of parameters, lack of longitudinal data. Conclusions: PDMS primarily occurs in females, mimics lupus panniculitis, and responds to therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.